What just happened? The FDA approved Cytokinetics’ Myqorzo on Friday, marking the company’s first U.S. drug approval after 27 years of development.
WASHINGTON, December 15, 2023 – After nearly three decades, Cytokinetics Corporation has finally secured its first U.S. drug approval. The Food and Drug Administration cleared Myqorzo, a new medicine designed to treat obstructive hypertrophic cardiomyopathy (HCM), an inherited heart disorder, on Friday.
A New Option for a Serious Condition
Obstructive HCM causes thickening of the heart muscle, making it harder for the heart to pump blood. Myqorzo works by selectively activating cardiac myosin, a protein essential for heart muscle contraction. This activation aims to improve heart function and alleviate symptoms.
Cytokinetics announced plans to begin selling Myqorzo in late January, though the price remains undisclosed. The drug will directly compete with a similar medication from Bristol Myers Squibb, approved in 2022, which is already generating over $1 billion in annual sales and continues to grow.
The approval represents a significant milestone for Cytokinetics, a biotech firm focused on developing innovative heart failure treatments. The company has invested heavily in research and development, and this approval validates its long-term strategy.
- The FDA approved Myqorzo for obstructive hypertrophic cardiomyopathy.
- This is Cytokinetics’ first U.S. drug approval after 27 years.
- Myqorzo will compete with a Bristol Myers Squibb drug already exceeding $1 billion in annual sales.
- The drug selectively activates cardiac myosin to improve heart function.
The competitive landscape in HCM treatment is heating up. Analysts predict that Myqorzo’s success will depend on its ability to demonstrate a clinical advantage over existing therapies and secure favorable reimbursement from insurers. The company will need to effectively communicate the drug’s benefits to both physicians and patients.